EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische Studie

Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis

Tom Konikoff, Nadav Loebl, Henit Yanai, Dror Libchik, Uri Kopylov, Ahmad Albshesh, Roni Weisshof, Itai Ghersin, Ahinoam Glusman Bendersky, Irit Avni-Biron, Yifat Snir, Hagar Banai und 4 weitere

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.06.008 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Tom Konikoff und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Infliximab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInfliximabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPrecision MedicineHumansFemaleMaleAdultMiddle AgedIsraelArtificial IntelligenceROC CurveTreatment OutcomeSeverity of Illness IndexMachine Learning

Stichwörter der Autor:innen

Artificial intelligenceClinical decision makingInflammatory bowel diseasesMachine learning

Substanzen

vedolizumabInfliximabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Rabin Medical Center Innovation Lab, Rabin Medical Center, Petah Tikva, Israel.
  • Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel.
  • Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Division of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel.
  • Division of Gastroenterology, Rambam Healthcare campus, Haifa, Israel; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Internal Medicine "D", Rabin Medical Center, Petah Tikva, Israel.

Zitieren

APA

Konikoff, T., Loebl, N., Yanai, H., Libchik, D., Kopylov, U., Albshesh, A., Weisshof, R., Ghersin, I., Bendersky, A. G., Avni-Biron, I., Snir, Y., Banai, H., Broytman, Y., Perl, L., Dotan, I., & Ollech, J. E. (2024). Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.06.008

Vancouver

Konikoff T, Loebl N, Yanai H, Libchik D, Kopylov U, Albshesh A, et al. Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.06.008

BibTeX
@article{Konikoff2024,
  author = {Konikoff, Tom and Loebl, Nadav and Yanai, Henit and Libchik, Dror and Kopylov, Uri and Albshesh, Ahmad and Weisshof, Roni and Ghersin, Itai and Bendersky, Ahinoam Glusman and Avni-Biron, Irit and Snir, Yifat and Banai, Hagar and Broytman, Yelena and Perl, Leor and Dotan, Iris and Ollech, Jacob E},
  title = {Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.06.008}
}
Kostenlos starten →